Clinical Pharmacokinetics

, Volume 2, Issue 4, pp 312–316 | Cite as

Current Literature References on Clinical Pharmacokinetics

Article
  • 7 Downloads

Keywords

Digoxin Clinical Pharmacology Clinical Pharmacokinetic Antipyrine Digitoxin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

Series 1

  1. Differenlial uptake of tritiated digoxin in benign and malignant central nervous system neoplasms. Williams, R.; Flanigan, S.; Bissen, J. et al.: American Journal of the Medical Sciences 272: 132 (1976).PubMedCrossRefGoogle Scholar
  2. Renal tubular handling of drugs. Cafruny, E.J.: American Journal of Medicine 62: 490 (1977).PubMedCrossRefGoogle Scholar
  3. Drug administration in renal failure. Cheigh, J.S.: American Journal of Medicine 62: 555 (1977)PubMedCrossRefGoogle Scholar
  4. Active drug metabolites and renal failure. Drayer, D.E.: American Journal of Medicine 62: 486 (1977).PubMedCrossRefGoogle Scholar
  5. Drug distribution in renal failure. Gibaldi, M.: American Journal of Medicine 62: 471 (1977).PubMedCrossRefGoogle Scholar
  6. Development of mechanisms for drug excretion. Hook, J.B. and Hewitt, W.R.: American Journal of Medicine 62: 497 (1977).PubMedCrossRefGoogle Scholar
  7. Pharmacokinetics in renal disease. Levy, G.: American Journal of Medicine 62: 461 (1977).PubMedCrossRefGoogle Scholar
  8. The binding of drugs to plasma proteins and the interpretation of measurements of plasma concentrations of drugs in patients with poor renal function. Reidenberg, M.M.: American Journal of Medicine 62: 466 (1977).PubMedCrossRefGoogle Scholar
  9. The biotransformation of drugs in renal failure. Reidenberg, M.M.: American Journal of Medicine 62: 482 (1977).PubMedCrossRefGoogle Scholar
  10. Combined seminar on the use of drugs in renal failure: narcotics, psychotherapeutic agents, antiarrhythmics, antihypertensives, sorbents, vitamin D and its analogues, anabolic hormones and nutritional supplements. Stenzel, K.H.; Reidenberg, M.M. and Rubin, A.L.: American Journal of Medicine 62: 527 (1977).CrossRefGoogle Scholar
  11. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Garver, D.L.; Dekirmenjian, H.; Davis, J.M. et al.: American Journal of Psychiatry 134: 304 (1977).PubMedGoogle Scholar
  12. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. Loughnan, P.M.; Greenwald, A.; Purton, W.W. et al.: Archives of Disease in Childhood 52: 302 (1977).PubMedCrossRefGoogle Scholar
  13. Statistic analysis of the median effective doses and plasma levels in epilepsy therapy. Oiler, L.; Laguans Hernandez, M.A.; Russi Tintore, A. et al.: Archives de Neurobiologia 40: 37 (1977).Google Scholar
  14. Fundamental and clinical studies on cefatrizine. Kawashima, S.; Kabasawa, T.; Takeda, H. et al.: Chemotherapy (Tokyo) 24: 1723 (1976).Google Scholar
  15. Fundamental and clinical studies of cefatrizine dry syrup in children. Kobayashi, Y.; Morikawa, Y. and Haruia, T.: Chemotherapy (Tokyo) 24: 1836 (1976).Google Scholar
  16. Laboratory and clinical studies for opththalmic application of cefatrizine. Matsuu, Y.; Mishima, K.; Nakamura, S. et al.: Chemotherapy (Tokyo) 24: 1976 (1976).Google Scholar
  17. Basic and clinical studies of cefatrizine in the obstetric and gynecological fields. Takase, Z.; Shirafuji, H. and Uchida, N.: Chemotherapy (Tokyo) 24: 1937 (1976).Google Scholar
  18. The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Marcus, F.I.; Quinn, E.J.; Horton, H. et al.: Circulation 55: 537 (1977).PubMedCrossRefGoogle Scholar
  19. Serum level monitoring and clinical pharmacokinetics of lithium. Amdisen, A.: Clinical Pharmacokinetics 2: 73 (1977).PubMedCrossRefGoogle Scholar
  20. Protein binding of coumarin anticoagulants in disease states. Bachmann, K. and Shapiro, R.: Clinical Pharmacokinetics 2: 110 (1977).PubMedCrossRefGoogle Scholar
  21. Clinical pharmacokinetics of hypnotics. Breimar, D.D.: Clinical Pharmacokinetics 2: 93 (1977).CrossRefGoogle Scholar
  22. Monitoring gold plasma levels in rheumatoid arthritis. Lorber, A.: Clinical Pharmacokinetics 2: 127 (1977).PubMedCrossRefGoogle Scholar
  23. Plasma protein binding of phenytoin and warfarin in patients undergoing renal transplantation. Odar-Cedarlof, I.: Clinical Pharmacokinetics 2: 147 (1977).CrossRefGoogle Scholar
  24. Pharmacokinetic evaluation of a patient with unusually high digoxin (D) requirements (Abstract). Flackenstein, L.; Benet, L.Z. and Thomson, P.D.: Clinical Pharmacology and Therapeutics 21: 102 (1977).Google Scholar
  25. Pharmacokinetics of d-propoxyphene in anephric patients (Abstract). Gibson, T.P.; Giacomini, K.H.; Briggs, W.A. et al.: Clinical Pharmacology and Therapeutics 21: 103 (1977).Google Scholar
  26. The effects of renal and liver disease on the disposition of clofibrate (Abstract). Gugler, R.; Kuerten, J.; Jensen, C. et al.: Clinical Pharmacology and Therapeutics 21: 106 (1977).Google Scholar
  27. Disposition of diazepam and its major metabolite desmethyl-diazepam in patients with liver disease. Klotz, U.; Antonin, K.H.; Bruegel, H. et al.: Clinical Pharmacology and Therapeutics 21: 430 (1977).PubMedGoogle Scholar
  28. Bioavailability, pharmacokinetics, and pharmacodynamics of minoxidil (M) in chronic renal failure (CRF) (Abstract). Lowenthal, D.T.; Nutterperl, R.E.; Zinne, G.: Clinical Pharmacology and Therapeutics 21: 109 (1977).Google Scholar
  29. Comparative pharmacokinetics of the vinca alkaloids in man (Abstract). Nelson, R.L.; Dyke, R.W. and Root, M.A.: Clinical Pharmacology and Therapeutics 21: 112 (1977).Google Scholar
  30. Lithium transport in red blood cells of manic depressive patients (Abstract). Pandey, G.N.; Davis, J.M.; Ostrow, D.G. et al.: Clinical Pharmacology and Therapeutics 21: 113 (1977).Google Scholar
  31. Timolol maleate (TM) pharmacokinetics in chronic renal disease (CRD) (Abstract). Pitone, J.M.; Lowenthal, D.T.; Onesti, G. et al.: Clinical Pharmacology and Therapeutics 21: 114 (1977).Google Scholar
  32. Chocolate and breast-feeding: theobromine pharmacokinetics in nursing mothers (Abstract). Resman, B.H.; Blumenthal, H.P. and Jusko, W.J.: Clinical Pharmacology and Therapeutics 21: 115 (1977).Google Scholar
  33. Plasma levels of chlorpromazine: Effect of age, chronicity of disease, and duration of treatment (Abstract). Rivera-Calimlim, L.; Nasrallah, H.; Gift, T. et al.: Clinical Pharmacology and Therapeutics 21: 115 (1977).Google Scholar
  34. Increased steady-state plasma levels and prolonged half-lives of tricyclic antidepressants in the elderly (Abstract). Robinson, D.S. and Nies, A.: Clinical Pharmacology and Therapeutics 21: 116 (1977).Google Scholar
  35. Vitamin K pharmacokinetics: Response in young and elderly patients (Abstract). Shepherd, A.M.M.; Wilson, N.M. and Stevenson, I.H.: Clinical Pharmacology and Therapeutics 21: 117 (1977).Google Scholar
  36. Rate and effect of debrisoquin in hypertensive patients (Abstract). Silas, J.H.; Lennard, M.S.; Smith, A.J. et al.: Clinical Pharmacology and Therapeutics 21: 117 (1977).Google Scholar
  37. Correlation of the blood and salivary levels of the beta-one blocker metoprolol (GP-2175) (Abstract). Wan, S.K. and Maronde, R.F.: Clinical Pharmacology and Therapeutics 21: 122 (1977).Google Scholar
  38. On the serum concentration and antipsychotic effects of thioridazine, thioridazine side-chain sulfoxide and thioridazine sidechain sulfone in chronic psychotic patients. Axelsson, R.: Current Therapeutic Research 21: 587 (1977).Google Scholar
  39. The concentration pattern of nonconjugated thioridazine metabolites in serum by thioridazine treatment and its relationship to physiological and clinical variables. Axelsson, R. and Martensson, E.: Current Therapeutic Research 21: 561 (1977).Google Scholar
  40. Pharmacokinetics and dosage of sulklomic and sulfamerazin in patients with a restricted renal function. Stein, G. and Traeger, A.: Deutsche Gesundheitawesen 32: 605 (1977).Google Scholar
  41. Phenytoin toxicity due to severe liver disease. Hull, R.L. and Pepping, J.: Drug Intelligence and Clinical Pharmacy 11: 57 (1977).Google Scholar
  42. Prednisone for chronic active liver disease: pharmokinetics, including conversion to prednisolone. Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Gastroenterology 72: 910 (1977).PubMedGoogle Scholar
  43. Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection. Compston, Juliet E. and Creamer, B.: Gut 18: 171 (1977).PubMedCrossRefGoogle Scholar
  44. Digoxin plasma levels: guide to effective treatment (Abstract). Danon, A.; Chen, Z. and Kaplanski, J.: Israel Journal of Medical Sciences 12: 1227 (1976).Google Scholar
  45. Tissue distribution and renal clearance of digoxin in infants (Abstract). Gorodischer, R.; Jusko, W.J. and Yaffe, S.J.: Israel Journal of Medical Sciences 12: 1228 (1976).Google Scholar
  46. Radioimmunoassay of haloperidol in human serum. Clark, B.R.; Tower, Barbara B. and Rubin, R.T.: Life Sciences 20: 319 (1977).PubMedCrossRefGoogle Scholar
  47. Pharmacokinetic and clinical aspects of glycoside therapy in cases of cardiac insufficiency. Rietbrock, N. and Kuhlmann, J.: Medizinische Klinik 72: 435 (1977).PubMedGoogle Scholar
  48. Saliva lithium levels: clinical applications. Neu, C. and DiMascio, A.: Psychopharmacology Bulletin 13: 55 (1977).PubMedGoogle Scholar
  49. Renal clearance of digoxin in young infants. Gorodischer, R.; Jusko, W.J. and Yaffe, S.J.: Research Communications in Chemical Pathology and Pharmacology 16: 363 (1977).PubMedGoogle Scholar
  50. Synovial-fluid pharmacokinetics of ketoprofen. Kennedy, A.C.: Rheumatology and Rehabilitation p.20 (1976).Google Scholar
  51. Serum levels of anticonvulsants and haemotological sequelae in black epileptics. Buchanan, N.; Bille, P.; Strickwood, B. et al.: South African Medical Journal 51: 504 (1977).PubMedGoogle Scholar
  52. Drug metabolism under pathological and abnormal physiological states in animals and man. Kato, R.: Xenobiotica 7: 25 (1977).PubMedCrossRefGoogle Scholar

Series 2

  1. Methotrexate therapy for psoriasis in elderly patients with impaired renal function. Weismann, K.: Acta Dermato-Venerologica 57: 185 (1977).Google Scholar
  2. On the absorption of proscillaridin A after single oral doses to normal and achlorhydric subjects. Andersson, K.E.; Bergdahl, B.; Bertler, A. et al.: Acta Pharmacologica et Toxicologica 40: 153 (1977).PubMedCrossRefGoogle Scholar
  3. Oxazepam disposition in uremic patients. Odar-Cederlof, I.; Vessman, J.; Alvan, G. et al.: Acta Pharmacologica et Toxicologica 40(Suppl. I): 52 (1977).PubMedGoogle Scholar
  4. Comparison of side-effects with coated lithium carbonate tablets and lithium preparations giving medium-slow and slow-release. A double-blind crossover study. Edstrom, A. and Persson, G.: Acta Psychiatrica Scandinavica 55: 153 (1977).PubMedCrossRefGoogle Scholar
  5. Lithium side-effects in relation to dose and to levels and gradients of lithium in plasma. Persson, G.: Acta Psychiatrica Scandinavica 55: 208 (1977).PubMedCrossRefGoogle Scholar
  6. Comparative clinical evaluation of lofepramine and imipramine: pharmacological aspects. Siwers, B.; Borg, S.; d’Elia, G. et al.: Acta Psychiatrica Scandinavica 55: 21 (1977).PubMedCrossRefGoogle Scholar
  7. Clozapine treatment of schizophrenic patients. Plasma concentrations and coagulation factors. Thorup, M. and Fog, R.: Acta Psychiatrica Scandinavica 55: 123 (1977).PubMedCrossRefGoogle Scholar
  8. Terminal half-lives of drugs studied in patients with hepatic diseases. Closson, R.G.: American Journal of Hospital Pharmacy 34: 520 (1977).PubMedGoogle Scholar
  9. Pharmacokinetics in drug therapy. II: application of clinical pharmacokinetics in the assessment of theophylline therapy. Floyd, R.A. and Cohen, J.L.: American Journal of Hospital Pharmacy 34: 402 (1977).PubMedGoogle Scholar
  10. Absolute bioavailability of oral theophylline. Hendeles, Leslie; Weinberger, M. and Bighley, L.: American Journal of Hospital Pharmacy 34: 525 (1977).PubMedGoogle Scholar
  11. Apparent theophylline half-life fluctuations during treatment of acute left ventricular failure. Jeane, J.W.; Chick, T.W.; Miller, D.A. et al.: American Journal of Hospital Pharmacy 34: 408 (1977).Google Scholar
  12. Plasma nortriptyline levels and ECG findings. Ziegler, V.E.; Bun Tee Co and Biggs, J.T.: Amer. J. Psychiatry 134: 441 (1977).Google Scholar
  13. Pharmacokinetics of some new aminoglycosic antibiotics: tobramycin, lividomycin, amikacin, sisomycin, in the patient with a normal renal function and in the patient with renal insufficiency, a guide for posology. Oksenhendler, G.; Leroy, A.; Humbert, G. et al.: Anesthesie Analgesie Reanimation 34: 93 (1977).Google Scholar
  14. Pharmacogenetics of drugs of importance in rheumatology. Omenn, G.A.: Arthritis and Rheumatism 20 (Suppl): 549 (1977).Google Scholar
  15. Dose finding for clinical trials of antiarrhythmic substances. Hahn, K.J.: Arzneimittel Forschung 27: 283 (1977).PubMedGoogle Scholar
  16. Preliminary observations on valproic acid kinetics in patients with epilepsy. Johannessen, S.I.: Arzneimittel-Forschung 27: 1083 (1977).PubMedGoogle Scholar
  17. Pharmacokinetic studies with valproic acid in man. Klotz, U.: Arzneimittel-Forschung 27: 1085 (1977).PubMedGoogle Scholar
  18. Dose finding for the bronchospasmolytic drugs in clinical practice. Lichterfeld, A.: Arzneimittel Forschung 27: 278 (1977).PubMedGoogle Scholar
  19. Dose finding in antibacterial chemotherapy. Metzger, K.: Arzneimittel Forschung 27: 286 (1977).PubMedGoogle Scholar
  20. Problems of dose finding sexual hormones. Neumann, F.; Elger, W.; Nishino, Y. et al.: Arzneimittel Forschung 27: 296 (1977).PubMedGoogle Scholar
  21. Example of dose finding in practice. Pharmacology of an antiarrhythmic agent. Oberdorf, A. and Raschack, M.: Arzneimittel Forschung 27: 281 (1977).PubMedGoogle Scholar
  22. Finding the effective dose of diuretics in man. Rupp, W.: Arzneimittel Forschung 27: 286 (1977).Google Scholar
  23. Psychic drugs: Predicting therapeutic effects and doses by test models with normal subjects. Taeuber, K.: Arzneimittel Forschung 27: 319 (1977).PubMedGoogle Scholar
  24. Metabolism of 14C-labelled alphaxalone in man. Strunin, I.; Strunin, J.M.; Knights, K.M. et al.: British Journal of Anaesthesia 49: 609 (1977).PubMedCrossRefGoogle Scholar
  25. An index for prescribing phenytoin in childhood. Albani, M.; Schulte, F.J. and Toseland, P.A.: British Journal of Clinical Pharmacology 4: 378 (1977).PubMedCrossRefGoogle Scholar
  26. Factors influencing the therapeutic response to gentamicin treatment in children. Ashurst, A.; Houston, I.B.; Mawer, G.E. et al.: British Journal of Clinical Pharmacology 4: 394P (1977).CrossRefGoogle Scholar
  27. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis. Calvey, T.N. and Chan, K.: British Journal of Clinical Pharmacology 4: 404P (1977).CrossRefGoogle Scholar
  28. Digoxin prescribing in perspective. Dobbs, Sylvia M.; Rodgers, Elaine M.; Kenyon, W.I. et al.: British Journal of Clinical Pharmacology 4: 327 (1977).Google Scholar
  29. Value of liver volume measurement in the study of antipyrine kinetics in liver disease. Halliwell, M.; Homeida, M. and Roberts, C.J.C.: British Journal of Clinical Pharmacology 4: 393P (1977).CrossRefGoogle Scholar
  30. Digoxin measurements in general practice. Holt, D.W.; Williamson, J.D. and Volans, G.N.: British Journal of Clinical Pharmacology 4: 321 (1977).PubMedCrossRefGoogle Scholar
  31. The absorption and elimination of ICI 74,917 in man. Pickup, M.E.; Johnson, A.J.; May, C.S. et al.: British Journal of Clinical Pharmacology 4: 357 (1977).PubMedCrossRefGoogle Scholar
  32. Absorption kinetics of aspirin and quinine in elderly subjects. Salem, S.A.M. and Stevenson, I.M.: British Journal of Clinical Pharmacology 4: 397P (1977).CrossRefGoogle Scholar
  33. Age as a determinant of sensitivity to warfarin. Shepherd, A.M.M.; Hewick, D.S.; Moreland, T.A. et al.: British Journal of Clinical Pharmacology 4: 315 (1977).PubMedCrossRefGoogle Scholar
  34. Factors influencing antipyrine elimination. The First Lilly Prize Lecture, University of Dundee, July 1976. Stevenson, I.H.: British Journal of Clinical Pharmacology 4: 261 (1977).PubMedCrossRefGoogle Scholar
  35. Sedation in liver disease. Leading article: British Medical Journal 1: 1241 (1977).Google Scholar
  36. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease. Forrest, J.A.H.; Finlayson, N.D.C.; Adjepon-Yamoah, K.K. et al.: British Medical Journal 1: 1384 (1977).PubMedCrossRefGoogle Scholar
  37. May mothers given warfarin breast-feed their infants? Orme, M.L’E.; Lewis, P.J.; De Swiet, M. et al.: British Medical Journal 1: 1564 (1977).PubMedCrossRefGoogle Scholar
  38. Phase I study of oral mitomycin C. Crooke, S.T.; Henderson, M.; Samson, M. et al.: Cancer Treatment Reports 60: 1633 (1976).PubMedGoogle Scholar
  39. Haloperidol concentrations in blood in cases of acute intoxication. Coutselinis, A.; Boukis, D. and Kentarchou, P.: Clinical Chemistry 23: 900 (1977).PubMedGoogle Scholar
  40. Influence of sex on drug kinetics in man. Giudicelli, J.F. and Tillement, J.P.: Clinical Pharmacokinetics 2: 157 (1977).PubMedCrossRefGoogle Scholar
  41. Drug kinetics in pregnancy. Krauer, Beatrice and Krauer, F.: Clinical Pharmacokinetics 2: 167 (1977).PubMedCrossRefGoogle Scholar
  42. Disease and acetylation polymorphism. Lunde, P.K.M.; Frislid, K. and Hansteen, V.; Clinical Pharmacokinetics 2: 182 (1977).PubMedCrossRefGoogle Scholar
  43. Pharmacokinetics and response to diazoxide in renal failure. Pearson, R.M.: Clinical Pharmacokinetics 2: 198 (1977).PubMedCrossRefGoogle Scholar
  44. Protein binding of cardiac glycosides in disease status. Storstein, L.: Clinical Pharmacokinetics 2: 220 (1977).PubMedCrossRefGoogle Scholar
  45. Interpretation of the serum digoxin concentration. Weintraub, M.: Clinical Pharmacokinetics 2: 205 (1977).PubMedCrossRefGoogle Scholar
  46. Relationship between blood level of atenolol and pharmacologic effect. Amery, A.; De Plaen, Jean-Francois; Lijnen, P. et al.: Clinical Pharmacology and Therapeutics 21: 691 (1977).PubMedGoogle Scholar
  47. Studies on digitalis. XII: Kinetic pattern of digitoxin metabolism in patients with biliary fistules. Storstein, L. and Amlie, J.: Clinical Pharmacology and Therapeutics 21: 659 (1977).PubMedGoogle Scholar
  48. Pharmacokinetics of cytosine arabinoside in acute myeloid leukemia. van Prooijen, R.; van der Kleijn, E. and Haanen, C.: Clinical Pharmacology and Therapeutics 21: 744 (1977).PubMedGoogle Scholar
  49. Serum levels of tobramycin in children. Da Nobrega, F.J.; De Mello, F.G.; Trabulsi, L.R. et al.: Current Therapeutic Research 21: 741 (1977).Google Scholar
  50. Pharmacokinetics of Bay g 2821 in the dog and in man. Ritter, W.: Current Medical Research and Opinion 4: 564 (1977).PubMedCrossRefGoogle Scholar
  51. Thioridazine metabolism and clinical response. A pilot study. Sakalis, G.; Traficante, L.J.; Gershon, S. et al.: Current Therapeutic Research 21: 720 (1977).Google Scholar
  52. Relationship between the antihypertensive effect and the drug plasma concentration of pindolol. Weiss, Y.A.; Loris, Y.; Safar, M.E. et al.: Current Therapeutic Research 21: 644 (1977).Google Scholar
  53. Post-mortem digoxin levels — two-unusual case reports. Dickson, S.J. and Blazey, N.D.: Forensic Science 9: 145 (1977).PubMedCrossRefGoogle Scholar
  54. Pharmacokinetics of cardiac glycosides and clinical significance. Rietbrock, N.; Kuhlmann, J. and Voehringer, H.F.: Fortschritte der Medizin 95: 909 (1977).PubMedGoogle Scholar
  55. Clinical pharmacology of cefadroxil and cephalexin, blood, urine and tissue concentrations in pregnancy at term. Fuentes-Calvo, V.R. et al.: Investigacion Medica Internacional 4: 3 (1977).Google Scholar
  56. The secretion of minocycline in sputum during therapy of bronchopulmonary infection in chronic chest diseases. Brogan, T.D.; Neale, L.; Ryley, H.C. et al.: Journal of Antimicrobial Chemotherapy 3: 247 (1977).PubMedCrossRefGoogle Scholar
  57. Warfarin elimination and responsiveness in patients with renal dysfunction. Bachmann, K.; Shapiro, D. and Mackiewicz, J.: Journal of Clinical Pharmacology 17: 292 (1977).PubMedGoogle Scholar
  58. The effects of ephedrine and theophylline on dexamethasone metabolism in bronchial asthma. Brooks, S.M.; Sholiton, L.P; Werk, E.E. Jr. et al.: J. Clin. Pharmacol. 308 (1977).Google Scholar
  59. Metabolic studies in patients with nadolol: oral and intravenous administration. Dreyfuss, J.; Brannick, L.J.; Vukovich, R.A. et al.: Journal of Clinical Pharmacology 17: 300 (1977).PubMedGoogle Scholar
  60. Maternal-fetal pharmacology activity of amikacin. Bernard, Betty; Abate, Micheline; Thielen, P.F. et al.: Journal of Infectious Diseases 135: 925 (1977).PubMedCrossRefGoogle Scholar
  61. Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness. Hall, W.H.; Gerding, Dale N. and Schierl, Elizabeth A.: Journal of Infectious Diseases 135: 957 (1977).PubMedCrossRefGoogle Scholar
  62. Comparison of concentrations of amoxicillin and ampicillin in serum and middle ear fluid of children with chronic otitis media. Klimek, J.J.; Nightingale, C; Lehmann, W.B. et al.: Journal of Infectious Diseases 135: 999 (1977).PubMedCrossRefGoogle Scholar
  63. Pharmacokinetics of methicillin in patients with cystic fibrosis. Yaffe, S.J.; Gerbracht, L.M.; Mosovich, L.L. et al.: Journal of Infectious Diseases 135: 828 (1977).PubMedCrossRefGoogle Scholar
  64. Clinical pharmacology of methicillin in neonates. Sarff, L.D.; McCracken, G.H.; Thomas, Marion L. et al.: Journal of Pediatrics 90: 1005 (1977).PubMedCrossRefGoogle Scholar
  65. Digitalis pharmacokinetics and therapy with respect to impaired renal function. Kramer, P.: Klinische Wochenschrift 55: 1 (1977).PubMedCrossRefGoogle Scholar
  66. Plasma digoxin levels in anuric patients and normal subjects taking digitoxin. Kramer, P.; Langescheid, G; Saul, J. et al.: Klinische Wochenschrift 55: 245 (1977).PubMedCrossRefGoogle Scholar
  67. Plasma concentrations after injection or infusion of phenytoin. Schmidt, D. and Vogel, A.: Klinische Wochenschrift 55: 219 (1977).PubMedCrossRefGoogle Scholar
  68. Cephalexin levels in the bronchial secretion of children. Daschner, F.: Munchener Medizinische Wochenschrift 119: 339 (1977).PubMedGoogle Scholar
  69. Plasma digoxin estimation in the newborn. Berdeaux, A.; Batisse, A.; Richer, Ch. et al: La Nouvelle Presse Medicale 6: 2142 (1977).PubMedGoogle Scholar
  70. Value of the estimation of anticonvulsants in the treatment of epilepsy. Loiseau, P.; Brachet-Liermam, A.; Legroux, M. et al: La Nouvelle Presse Medicale 6: 813 (1977).PubMedGoogle Scholar
  71. Relationship between anti-hypertensive action and plasma concentration of pindolol. Weiss, Y.; Lona, Y.; Lavene, D. et al: La Nouvelle Presse Medicale 6: 927 (1977).PubMedGoogle Scholar
  72. Placenlal transfer and metabolism of beta-methasone in human pregnancy. Anderson, Anne B.M.; Gennser G.; Jeremy, J.Y. et al: Obstetrics and Gynecology 49: 471 (1977).PubMedGoogle Scholar
  73. Amikacin pharmacokinetics in the therapy of childhood urinary tract infections. Khan, A.J.; Evans, H.E.; Jhaven, R. et al: Pediatrics 58: 873 (1976).PubMedGoogle Scholar
  74. Serum concentration and serum half-life of digoxin in premature and mature newborns. Lang, D. and von Bernuth, G.: Pediatrics 59: 902 (1977).PubMedGoogle Scholar
  75. Clinical pharmacology of anaesthetic agents and anaesthetic adjuvants in renal insufficiency. Stoeckel, H.: Praktische Anaethesie Wiederbelebung und Intensivtherapie 12: 97 (1977).Google Scholar
  76. Plasma nortnptyline and clinical response — a study using changing plasma levels. Burrows, G.D.; Maguire, K.P.; Scoggins, B.A. et al: Psychological Medicine 7: 87 (1977).PubMedCrossRefGoogle Scholar
  77. Concentrations of oxyteiracycline, tetracycline and doxycycline in mandibular osteitis. Bystedt, N.; Dornbusch, K. and Nord, C.E.: Scandinavian Journal of Infectious Diseases p 37 (1976).Google Scholar
  78. Concentration of doxycycline in bowel tissue and postoperative infections. Hoejer, H. and Wettcrfors, J.: Scandinavian Journal of Infectious Diseases Suppl No 9: 100 (1976).Google Scholar
  79. The elimination of tritiated doxycychne in normal subjects and in patients with severely impaired renal function. Mahon, W.A.; Johnson, G.E.; Endrenyi, L. et al.: Scandinavian Journal of Infectious Diseases Suppl No 9: 24 (1976).Google Scholar
  80. The concentration of doxycychne in human prostate gland and its role in the treatment of prostitis. Oosterlinck, W.; Wallijn, E. and Wijndaele, J.J.: Scandinavian Journal of Infectious Diseases Suppl No 9: 85 (1976).Google Scholar
  81. The hazards of drug prescription in patients with liver cirrhosis. Caulin, C.; Wagner, J.C. and Lamotte, M.: Semaine des Hopitaux Therapeutique 53: 109 (1977).PubMedGoogle Scholar
  82. Raised serum transaminase levels in patients with rheumatic fever treated with salicylates. Gitlin, N. and Grant, J.: South African Medical Journal 51: 697 (1977).PubMedGoogle Scholar
  83. The influence of biliary disease on the excretion of cefazohn in human bile. McLeish, A. E.; Strachan, C.J.L.; Powis, S.J.A. et al: Surgery 81: 426 (1977).PubMedGoogle Scholar
  84. Phenformin blood levels on usual therapeutic dosage. Catellier, C.; Fraser, E. and Ayotte-Ferron, L.: L’Union Medicale du Canada 106: 323 (1977).PubMedGoogle Scholar
  85. Comparative studies of placental diffusion of propanidid (sombrevin) and barbiturate in premature and caesanar births. Yarga, J.; Kiszel, J.; Csomor, S.; Balazsvargo, N. et al: Zentralblatt fur Gynaekologie 99: 343 (1977).Google Scholar

Copyright information

© ADIS Press 1977

Personalised recommendations